Gaspar C, Donders G G, Palmeira-de-Oliveira R, Queiroz J A, Tomaz C, Martinez-de-Oliveira J, Palmeira-de-Oliveira A
Labfit-HPRD: Health Products Research and Development, Lda, Covilhã, Portugal.
CICS-UBI: Health Sciences Research Centre, Covilhã, Portugal.
AMB Express. 2018 Sep 27;8(1):153. doi: 10.1186/s13568-018-0679-z.
In the last years, the use of probiotics, including Lactobacillus species, has received much attention to prevent and treat vaginal disorders. These species have been described as having the ability to colonize the epithelial surface and produce antimicrobial metabolites that are able to control the remaining vaginal microflora. This study aimed to identify and characterize, for the first time, a bacteriocin natively produced by Lactobacillus acidophilus KS400 (probiotic strain from Gynoflor-Medinova AG, Switzerland) and its antimicrobial activity against relevant urogenital pathogens. After organic acids and hydrogen peroxide neutralization in the fermented Lactobacillus acidophilus KS400 culture medium, bacteriocin activity was tested against the indicator microorganism Lactobacillus delbrueckii ATCC9649. The fermentation of Lactobacillus acidophilus KS400 for bacteriocin production was carried out in batch mode, and its antimicrobial activity, optical density and pH were monitored. After production and extraction, the bacteriocin molecular weight was estimated by electrophoresis and tested against vaginal pathogenic microorganisms. As described for other bacteriocins, batch fermentation profiles indicated that bacteriocin production occurs during the exponential growth phase of the lactobacilli, and declines during their stationary growth phase. The molecular weight of the bacteriocin is approximately 7.5 kDa. The bacteriocin containing protein extract was shown to inhibit the growth of Gardnerella vaginalis, Streptococcus agalactiae, Pseudomonas aeruginosa and the indicator strain Lactobacillus delbrueckii ATCC9649. We conclude that L. acidophilus KS400 produces bacteriocin with antimicrobial activity against relevant urogenital pathogens.
在过去几年中,包括乳酸杆菌属在内的益生菌在预防和治疗阴道疾病方面受到了广泛关注。这些菌种被描述为具有定殖于上皮表面并产生能够控制其余阴道微生物群的抗菌代谢产物的能力。本研究旨在首次鉴定和表征嗜酸乳杆菌KS400(来自瑞士吉诺弗洛 - 梅迪诺瓦公司的益生菌菌株)天然产生的一种细菌素及其对相关泌尿生殖病原体的抗菌活性。在嗜酸乳杆菌KS400发酵培养基中中和有机酸和过氧化氢后,针对指示微生物德氏乳杆菌ATCC9649测试细菌素活性。嗜酸乳杆菌KS400产细菌素的发酵以分批模式进行,并监测其抗菌活性、光密度和pH值。生产和提取后,通过电泳估计细菌素的分子量,并针对阴道致病微生物进行测试。如其他细菌素所述,分批发酵曲线表明细菌素的产生发生在乳酸杆菌的指数生长期,并在其稳定生长期下降。该细菌素的分子量约为7.5 kDa。含细菌素的蛋白提取物显示出能抑制阴道加德纳菌、无乳链球菌、铜绿假单胞菌以及指示菌株德氏乳杆菌ATCC9649的生长。我们得出结论,嗜酸乳杆菌KS400产生的细菌素对相关泌尿生殖病原体具有抗菌活性。